MABPHARM-B (02181) released its interim results, with shareholders' profit attributable amounting to 31.36 million yuan, a year-on-year increase of 982.1%.

22:28 28/08/2026

Maibo Pharmaceutical-B (02181) announced its interim results for the six months ending June 30, 2026, with the group's operating income reaching RMB 398 million, a year-on-year increase of 45.1%; the profit attributable to shareholders was RMB 31.36 million, a significant year-on-year increase of 982.1%; earnings per share were RMB 0.01.

MABPHARM-B (02181) released its interim results for the six months ending June 30, 2026, with the group reporting revenue of RMB 398 million, a year-on-year increase of 45.1%; shareholders' profit attributable to the company was RMB 31.36 million, a year-on-year increase of 982.1%; earnings per share were RMB 0.01.

SIS INT'L (00529) released its interim results, with a profit attributable to shareholders of HKD 56.852 million, a decrease of 37.81% compared to the same period last year.

FEIYANG GROUP (01901) announced its interim results, with a profit attributable to shareholders of 6.641 million, an increase of 0.21% year-on-year.

STRONG PETRO (00852) released its interim results, reporting a loss attributable to shareholders of HKD 146 million, a year-on-year increase of 128.07%.

SIS INT'L (00529) released its interim results, with a profit attributable to shareholders of HKD 56.852 million, a decrease of 37.81% compared to the same period last year.

FEIYANG GROUP (01901) announced its interim results, with a profit attributable to shareholders of 6.641 million, an increase of 0.21% year-on-year.

STRONG PETRO (00852) released its interim results, reporting a loss attributable to shareholders of HKD 146 million, a year-on-year increase of 128.07%.